Skip to menu Skip to content Skip to footer

2021

Journal Article

Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol

Ullman, Amanda J., August, Deanne, Kleidon, Tricia, Walker, Rachel, Marsh, Nicole M., Bulmer, Andrew, Pearch, Benjamin, Runnegar, Naomi, Schults, Jessica A., Leema, Joanne, Lee-Archer, Paul, Biles, Cathy, Southam, Katrina, Gibson, Victoria, Byrnes, Joshua, Ware, Robert S., Chopra, Vineet, Coulthard, Alan, Mollee, Peter, Rickard, Claire M. and Harris, Patrick N. A. (2021). Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol. BMJ Open, 11 (4) e042475, 1-7. doi: 10.1136/bmjopen-2020-042475

Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol

2021

Journal Article

Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w)

Burgess, M., Chen, Y. C.E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2021). Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w). Oncogene, 40 (6), 1203-1203. doi: 10.1038/s41388-020-01619-y

Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w)

2021

Journal Article

SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients

Chen, Yu-Chen Enya, Burgess, Melinda, Mapp, Sally, Mollee, Peter, Gill, Devinder, Blumenthal, Antje and Saunders, Nicholas A. (2021). SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients. Frontiers in Immunology, 11 610523, 1-12. doi: 10.3389/fimmu.2020.610523

SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients

2021

Journal Article

Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial

Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John and Weisel, Katja (2021). Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial. Journal of Clinical Oncology, 39 (3), 227-237. doi: 10.1200/JCO.20.01370

Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial

2021

Journal Article

The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft

Rees, Matthew J., Mollee, Peter, Ng, Jun Yen, Murton, Alex, Gonsalves, Jose Filipe, Panigrahi, Ashish, Beer, Hayley, Loh, Joanna, Nguyen, Philip, Hunt, Sam, Jina, Hayden, Wayte, Rebecca, Sutrave, Gaurav, Tan, Jocelyn, Abeyakoon, Chathuri, Chee, Ashlyn, Augustson, Bradley, Kalro, Akash, Lee, Cindy, Agrawal, Shivam, Churilov, Leonid, Chua, Chong Chyn, Lim, Andrew Boon Ming, Zantomio, Daniela and Grigg, Andrew (2021). The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transplantation, 56 (9), 2152-2159. doi: 10.1038/s41409-021-01300-2

The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft

2021

Journal Article

The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia

Murali, Aarya, Cross, Donna and Mollee, Peter (2021). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia. Blood Cancer Journal, 11 (1) 6, 6. doi: 10.1038/s41408-020-00401-3

The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia

2021

Journal Article

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma

Tobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma

2021

Journal Article

Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting

Smith, Joel D, Wijeratne, Nilika, Schneider, Hans G, de Malmanche, Theo, Hissaria, Pravin, Toit, Stephen Du, Chiu, Weldon, Boyder, Conchita, Morison, Ian M, Tseng, Anfernee, Glegg, Kaye, Wienholt, Louise, Mollee, Peter and on behalf of the AACB/RCPA Monoclonal Gammopathy Working Party (2021). Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. Clinical Biochemist Reviews, 42 (1), 11-16. doi: 10.33176/AACB-21-00001

Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting

2020

Journal Article

Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices

Ellis, Marc L., Okano, Satomi, McCann, Andrew, McDowall, Angela, Van Kuilenburg, Rosita, McCarthy, Alexandra L., Joubert, Warren, Harper, John, Jones, Mark and Mollee, Peter (2020). Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal, 50 (12), 1475-1482. doi: 10.1111/imj.14780

Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices

2020

Journal Article

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Mollee, Peter, Reynolds, John, Janowski, Wojt, Quach, Hang, Campbell, Philip, Gibbs, Simon D., Lee, Sophie, D'Rozario, James, Taylor, Kerry, Cochrane, Tara, Wallington-Beddoe, Craig Thomas, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian H., Weston, Helen, Ho, Phoebe Joy, Horvath, Noemi, Yuen, Flora and Spencer, Andrew (2020). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 136 (Supplement 1), 4-5. doi: 10.1182/blood-2020-138394

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

2020

Journal Article

Physical activity in people with multiple myeloma: associated factors and exercise program preferences

Nicol, Jennifer L., Woodrow, Carmel, Burton, Nicola W., Mollee, Peter, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2020). Physical activity in people with multiple myeloma: associated factors and exercise program preferences. Journal of Clinical Medicine, 9 (10) 3277, 3277-11. doi: 10.3390/jcm9103277

Physical activity in people with multiple myeloma: associated factors and exercise program preferences

2020

Journal Article

Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis

Kastritis, Efstathios, Leleu, Xavier, Arnulf, Bertrand, Zamagni, Elena, Cibeira, Maria Teresa, Kwok, Fiona, Mollee, Peter, Hajek, Roman, Moreau, Philippe, Jaccard, Arnaud, Schonland, Stefan O., Filshie, Robin, Nicolas-Virelizier, Emmanuelle, Augustson, Bradley, Mateos, Maria-Victoria, Wechalekar, Ashutosh, Hachulla, Eric, Milani, Paolo, Dimopoulos, Meletios A., Fermand, Jean-Paul, Foli, Andrea, Gavriatopoulou, Maria, Klersy, Catherine, Palumbo, Antonio, Sonneveld, Pieter, Erik Johnsen, Hans, Merlini, Giampaolo and Palladini, Giovanni (2020). Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. Journal of Clinical Oncology, 38 (28), 3252-3260. doi: 10.1200/JCO.20.01285

Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis

2020

Journal Article

Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial

Mollee, P., Okano, S., Abro, E., Looke, D., Kennedy, G., Harper, J., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Jones, M. (2020). Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial. Journal of Hospital Infection, 106 (2), 335-342. doi: 10.1016/j.jhin.2020.07.021

Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial

2020

Journal Article

HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients

Burgess, M., Chen, U. C. E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2020). HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients. Oncogene, 39 (35), 5756-5767. doi: 10.1038/s41388-020-01394-w

HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients

2020

Journal Article

Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL

Burgess, Melinda, Chen, Yu Chen Enya, Mapp, Sally, Mollee, Peter, Gill, Devinder and Saunders, Nicholas A. (2020). Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL. Leukemia and Lymphoma, 61 (11), 1-5. doi: 10.1080/10428194.2020.1775211

Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL

2020

Journal Article

Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance

Weinkove, Robert, McQuilten, Zoe K, Adler, Jonathan, Agar, Meera R, Blyth, Emily, Cheng, Allen C, Conyers, Rachel, Haeusler, Gabrielle M, Hardie, Claire, Jackson, Christopher, Lane, Steven W, Middlemiss, Tom, Mollee, Peter, Mulligan, Stephen P, Ritchie, David, Ruka, Myra, Solomon, Benjamin, Szer, Jeffrey, Thursky, Karin A, Wood, Erica M, Worth, Leon J, Yong, Michelle K, Slavin, Monica A and Teh, Benjamin W (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Medical Journal of Australia, 212 (10) mja2.50607, 481-489. doi: 10.5694/mja2.50607

Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance

2020

Journal Article

Bortezomib use and outcomes for the treatment of multiple myeloma

Loke, Crystal, Mollee, Peter, McPherson, Ian, Walpole, Euan, Yue, Mimi, Mutsando, Howard, Wong, Phillip, Weston, Helen, Tomlinson, Ross and Hollingworth, Samantha (2020). Bortezomib use and outcomes for the treatment of multiple myeloma. Internal Medicine Journal, 50 (9) imj.14886, 1059-1066. doi: 10.1111/imj.14886

Bortezomib use and outcomes for the treatment of multiple myeloma

2020

Journal Article

A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group

Maqbool, M. Gohar, Tam, Constantine S., Morison, Ian M., Simpson, David, Mollee, Peter, Schneider, Hans, Chan, Henry, Juneja, Surender, Harvey, Yasmin, Nath, Lakshmi, Hissaria, Pravin, Prince, H. Miles, Wordsworth, Helen, Opat, Stephen and Talaulikar, Dipti (2020). A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 52 (2), 167-178. doi: 10.1016/j.pathol.2019.11.002

A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group

2020

Journal Article

Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome

Mohamed, Ahmed, Collins, Joel, Jiang, Hui, Molendijk, Jeffrey, Stoll, Thomas, Torta, Federico, Wenk, Markus R., Bird, Robert J., Marlton, Paula, Mollee, Peter, Markey, Kate A. and Hill, Michelle M. (2020). Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. PloS One, 15 (1) e0227455, e0227455. doi: 10.1371/journal.pone.0227455

Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome

2019

Journal Article

Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status

Harwood, Matthew, Dunn, Nathan, Moore, Julie, Mollee, Peter and Hapgood, Greg (2019). Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status. Leukemia & Lymphoma, 61 (3), 1-7. doi: 10.1080/10428194.2019.1688322

Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status